Insulet EVP of Innovation and Strategy Eric Benjamin [Photo courtesy of Insulet]
DIABETES CARE
Insulet EVP of Innovation and Strategy Eric Benjamin
Benjamin discussed the new Omnipod 5 automated insulin delivery system and the future of diabetes care: “Two huge sources of burden — thinking about what’s going to happen to blood sugar and the need to take out and carry a separate device — that’s automated with Omnipod 5. It’s truly extraordinary technology. The feedback in our first few months of the launch has been extraordinary. … It is definitely a platform that we will build on. If you zoom way out, Omnipod 5 is a microcosm of what we think the world is going to look like 20 or 30 years from now with true, personalized delivery for a range of drugs in response to biomarkers that are detected via novel sensors to get therapy just right.”
Benjamin said Insulet engineers simulate use to determine what needs to change with each version of Omnipod.
“They see when things work better or less well — they experience it,” Benjamin said. It’s a huge help in providing empathy for what users are going to experience. It’s a huge part of understanding the design that they’re working on, and it’s a huge part of providing context. … That’s probably the single most important thing that we do very early in development.”
Read more: Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
